An open label, phase II, multicenter, study to evaluate the efficacy and safety of pertuzumab (P) in chemotherapy naïve patients (pts) with hormone refractory prostate cancer (HRPC)

Bono, Johann S. de; Bellmunt, Joaquim; Droz, J. P.; Miller, Kelsey; Zugmaier, Gerhard; Sternberg, C.; Gimenez, V.; Parker, Charles J.; Mason, Meredith C.; Graham, Jill

doi:10.1200/jco.2005.23.16_suppl.4609

Cited by 5 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date several phase II trials evaluating pertuzumab have been completed. Initial results evaluating pertuzumab as monotherapy in metastatic breast cancer and hormone-refractory prostate cancer were not promising as there was limited evidence of activity in breast cancer patients and no prostate-specific antigen responses in the prostate cancer (Cortes et al, 2005;de Bono et al, 2005). However, more promising results in refractory or recurrent ovarian cancer have been seen in which clinical activity was seen in 15% of patients .…”

Section: Targeting the Raf-mek-erk Mapk Cascade Pj Roberts And Cj Dermentioning

confidence: 97%

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

2007

View full text Add to dashboard Cite

Section: Targeting the Raf-mek-erk Mapk Cascade Pj Roberts And Cj Dermentioning

confidence: 97%

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

2007

View full text Add to dashboard Cite

“…Signalling mediated through ErbB2/ErbB3 is implicated in AR activation through effects on AR DNA binding and stability (Mellinghoff et al, 2004). However, phase II studies of single agent ErbB signalling pathway inhibitors, including gefitinib (a small molecule EGFR tyrosine kinase inhibitor), trastuzumab (a monoclonal antibody to HER2) and pertuzumab (a HER2 dimerisation inhibitor) have reported no clinically significant activity in unselected CRPC patients (Ziada et al, 2004;Canil et al, 2005;de Bono et al, 2005).…”

Section: Erbb Receptorsmentioning

confidence: 99%

Improving the outcome of patients with castration-resistant prostate cancer through rational drug development

et al. 2006

View full text Add to dashboard Cite

Castration-resistant prostate cancer (CRPC) is now the second most common cause of male cancer-related mortality. Although docetaxel has recently been shown to extend the survival of patients with CRPC in two large randomised phase III studies, subsequent treatment options remain limited for these patients. A greater understanding of the molecular causes of castration resistance is allowing a more rational approach to the development of new drugs and many new agents are now in clinical development. Therapeutic targets include the adrenal steroid synthesis pathway, androgen receptor signalling, the epidermal growth factor receptor family, insulin growth factor-1 receptor, histone deacetylase, heat shock protein 90 and the tumour vasculature. Drugs against these targets are giving an insight into the molecular pathogenesis of this disease and promise to improve patient quality of life and survival. Finally, the recent discovery of chromosomal translocations resulting in the upregulation of one of at least 3 ETS genes (ERG, ETV1, ETV4) may lead to novel agents for the treatment of this disease.

show abstract

“…A phase II study was also conducted to determine the efficacy of pertuzumab in chemotherapy-naive patients with hormone-refractory prostate cancer. No prostatespecific antigen responses were observed (32). Phase II evaluation of pertuzumab in refractory or recurrent ovarian cancer yielded somewhat more promising results, with objective tumor responses or CA125 responses in 15% of patients (33).…”

Section: Monoclonal Antibodies Targeting Egfrmentioning

confidence: 95%

Epidermal Growth Factor Receptor Inhibitors in Development for the Treatment of Non–Small Cell Lung Cancer

Heymach

Nilsson

Blumenschein³

et al. 2006

Clinical Cancer Research

View full text Add to dashboard Cite

The epidermal growth factor receptor (EGFR) inhibitors erlotinib, gefitinib, and cetuximab have undergone extensive clinical testing and have established clinical activity in non^small cell lung cancer and other types of solid tumors. A number of newer inhibitors are currently in clinical development with different spectra of activity or mechanisms of receptor inhibition.These include monoclonal antibodies, such as panitumumab and matuzumab; dual inhibitors of EGFR and vascular endothelial growth factor receptor, such as ZD6474 and AEE788; inhibitors of multiple EGFR family members, such as lapatinib; and irreversible inhibitors, such as canertinib and HKI272. Preclinical studies suggest that several of these agents may have activity in tumors refractory to erlotinib or gefitinib. Among these agents, ZD6474 has undergone the most extensive clinical testing. The antitumor activity of ZD6474 in these two randomized phase II clinical trials in patients with non^small cell lung cancer was felt to be sufficiently promising to warrant phase III clinical testing. Several of the other EGFR inhibitors are also undergoing advanced clinical testing, either alone or in combination with other agents. EGFR has now been validated as a clinically relevant target, and several different types of agents inhibiting this receptor are currently in development. Future research will be needed to elucidate the role of these agents in patients with EGFR inhibitor^naive and EGFR inhibitor^refractory disease, to define the molecular characteristics that predict response, and to determine whether these drugs should be used in combination with other targeted agents or chemotherapy.

show abstract

An open label, phase II, multicenter, study to evaluate the efficacy and safety of pertuzumab (P) in chemotherapy naïve patients (pts) with hormone refractory prostate cancer (HRPC)

Cited by 5 publications

References 0 publications

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

Improving the outcome of patients with castration-resistant prostate cancer through rational drug development

Epidermal Growth Factor Receptor Inhibitors in Development for the Treatment of Non–Small Cell Lung Cancer

Contact Info

Product

Resources

About